May 06, 2026
A federal court Wednesday signed off on a consent judgment in a patent case brought by a Johnson & Johnson unit that prevents Tolmar Inc. from selling a generic version of the blockbuster schizophrenia drug Invega Sustenna.
June 14, 2024
A federal court has refused to reconsider a March decision finding Tolmar failed to show a patent on Janssen's blockbuster schizophrenia drug Invega Sustenna was invalid as obvious.
March 01, 2024
Johnson & Johnson has persuaded a federal judge in Wilmington, Delaware, to rule in its favor in a patent case seeking to prevent a startup from launching a competing line of schizophrenia drugs, in part because Invega Sustenna has made the pharmaceutical giant billions of dollars.